Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.

Tavapadon Sets Development Benchmark for Parkinson's

Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.

KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer

Videos

Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry. 

PharmTech’s Weekly Roundup—September 25, 2026

The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.

Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark

The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.

EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy

Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River. Dr. Aleksandra Zuraw is a board-certified senior toxicologic pathologist at Charles River Laboratories and a long-time leader in digital pathology and image analysis. She has worked extensively with AI tools and digital workflows since the early stages of her career, contributing to the development and validation of image analysis solutions across several organizations. Dr. Zuraw is the coauthor of several peer-reviewed publications on digital pathology and image analysis, and the author of the book 

"Digital Pathology 101: Everything you need to know to start and continue your digital pathology journey."

 Originally from Poland, she completed her pathology training in Berlin, Germany, and has worked across six countries. She also founded the online educational platform Digital Pathology Place, where she creates content and training materials that help bridge the gap between digital pathology innovation and practical application. Through her global perspective and commitment to education, Dr. Zuraw continues to shape the integration of AI and digital pathology in veterinary pathology.

In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.

Pharma Fundamentals: Digital Pathology in Drug Development, Part 1

Cheryl Barton is director of PharmaVision, 

Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.

Sweden, a Powerhouse for Early Stage Innovation

The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.

The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push

The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.

Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity

This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.